相关实验视频

Updated: Jul 7, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis

Published on: February 9, 2021

7-甲基丁通过增加其可溶性来抑制单酸盐晶体的形成

Antonia Costa-Bauza¹, Felix Grases¹

¹Laboratory of Renal Lithiasis Research, University Institute of Health Science Research (IUNICS-IdISBa), University of Balearic Islands, Ctra. de Valldemossa km 7.5, 07122 Palma, Spain.

|December 23, 2023

概括

7-甲基丁有效地防止单酸盐晶体的形成,这是痛风的关键因素. 这一发现表明,通过使用甲基丁 (methylxanthine) 来预防痛风的潜在治疗策略.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
结晶学结晶学结晶学

背景情况:

痛风是一种代谢障碍,其特点是酸盐 (MSU) 晶体在关节中的沉积.
了解影响MSU结晶形成的因素对于开发有效的痛风治疗至关重要.

研究的目的:

研究各种甲基丁衍生物和甲基化尿酸化合物的对MSU晶体形成的影响.
为了确定可以抑制或阻止MSU晶体发育的特定化合物.

主要方法:

实验室研究使用模拟的突液介质进行.
添加了9种甲基丁和2种甲基化尿酸衍生物,以评估它们在96小时内对MSU晶体形成的影响.
在受控条件下 (25°C,pH 7.4,0.4 M Na+) 监测晶体形成.

主要成果:

7-甲基丁表现出显著的抑制,完全防止MSU晶体的形成,度为6×10-5M.
1-甲基丁,3-甲基丁,7-甲基酸和1,3-二甲基酸的抑制作用较弱.
其他经过测试的甲基丁 (神胺,咖啡因,神林,二林,乙林,氧林) 并没有直接抑制晶体形成.

结论:

7-甲基丁是一种强大的MSU晶体形成的抑制剂,可能是通过改变热力学而不是动力学来改变.
口服7-甲基丁或代谢为其的化合物 (如神胺) 可能为痛风预防提供一种新的治疗方法.
对甲基丁衍生物的进一步研究可能会导致新的痛风治疗策略.

关键词:

7 - 甲基丁的使用方法痛风是一种痛风.单尿酸盐是一种酸盐.可溶性增强提高可溶性

更多相关视频

Syntheses, Crystallization, and Spectroscopic Characterization of 3,5-Lutidine N-Oxide Dehydrate

Syntheses, Crystallization, and Spectroscopic Characterization of 3,5-Lutidine N-Oxide Dehydrate

Published on: April 24, 2018

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

相关概念视频

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...

Antihypertensive Drugs: Thiazide-Class Diuretics

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...

Phase II Reactions: Glucuronidation

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...

Cholinergic Antagonists: Pharmacological Actions

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...